Literature DB >> 34012660

The deficiency of FKBP-5 inhibited hepatocellular progression by increasing the infiltration of distinct immune cells and inhibiting obesity-associated gut microbial metabolite.

Chuantao Zhang1, Xiang Cui2, Lian Feng3, Zhiyi Han2, Deti Peng2, Wenjun Fu4, Yufeng Xing2.   

Abstract

BACKGROUND: Gut microbiota has a number of essential roles in nutrition metabolism and immune homeostasis, and is closely related to hepatocellular progression. In recent years, studies have also shown that FK506 binding protein 5 (FKBP-5) plays a crucial role in immune regulation. However, it is not yet clear whether FKBP-5 promotes the development of hepatocellular carcinoma (HCC) by affecting immune function and gut microbiota.
METHODS: FKBP-5 expression was verified by immunochemistry and western blot and reverse transcription polymerase chain reaction (RT-qPCR) assays. After treatment in WT and FKBP-5-/- mice, the histological characteristic of mice liver tissue was assessed by H&E staining, and hepatic leukocytes and hepatic NKT cells were identified by flow cytometer. Meanwhile, primary bile acids (BAs), secondary BAs, serum total cholesterol, and the weight of abdomen adipose tissues were examined, and the gut microbiota was evaluated by 16S ribosomal ribonucleic acid (rRNA) sequencing.
RESULTS: We discovered that FKBP-5 was highly expressed in HCC tissues. Meanwhile, FKBP-5 deletion inhibited tumor progression by increasing CD8+ T, CD4+ T, NKT and CD4+NKT cells in mice after diethylnitrosamine (DEN) injection. Besides, we proved that FKBP-5 deletion generated rapid and significant reductions in the intestinal BAs, the weight of abdomen adipose tissues and the serum total cholesterol. FKBP-5 deletion also led to a change in the composition of gut microbiota, suggesting that BAs are the main dietary factor regulating gut microbiota, which could be affected by FKBP-5 deletion. Further, we uncovered that anti-CD4 and anti-CD8 treatments facilitated hepatocellular progression by modulating gut microbiota composition in FKBP-5-/- mice.
CONCLUSIONS: Therefore, we demonstrated that FKBP-5 deletion inhibited hepatocellular progression by modulating immune response and gut microbiome-mediated BAs metabolism. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  FK506 binding protein 51; bile acids; gut microbiota; hepatocellular carcinoma (HCC); immune cells

Year:  2021        PMID: 34012660      PMCID: PMC8107620          DOI: 10.21037/jgo-21-71

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  58 in total

Review 1.  Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.

Authors:  Jian-Wen Jiang; Xin-Hua Chen; Zhigang Ren; Shu-Sen Zheng
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2018-11-22

Review 2.  [Gut microbiota may have influence on glucose and lipid metabolism].

Authors:  Kristian Hallundbæk Mikkelsen; Morten Frost Nielsen; Michael Tvede; Torben Hansen; Oluf Borbye Pedersen; Jens Juul Holst; Tina Vilsbøll; Filip Krag Knop
Journal:  Ugeskr Laeger       Date:  2013-11-11

Review 3.  Glucocorticoids, genes and brain function.

Authors:  Grzegorz R Juszczak; Adrian M Stankiewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-11-24       Impact factor: 5.067

4.  Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury.

Authors:  Jana C Mossanen; Oliver Krenkel; Can Ergen; Olivier Govaere; Anke Liepelt; Tobias Puengel; Felix Heymann; Sandra Kalthoff; Eric Lefebvre; Dirk Eulberg; Tom Luedde; Gernot Marx; Christian P Strassburg; Tania Roskams; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2016-07-22       Impact factor: 17.425

5.  Bacterial communities in the small intestine respond differently to those in the caecum and colon in mice fed low- and high-fat diets.

Authors:  Janet C Onishi; Sara Campbell; Michael Moreau; Falshruti Patel; Andrew I Brooks; Yin Xiu Zhou; Max M Häggblom; Judith Storch
Journal:  Microbiology       Date:  2017-07-26       Impact factor: 2.777

6.  Loss of FKBP5 impedes adipocyte differentiation under both normoxia and hypoxic stress.

Authors:  Lingling Zhang; Bin Qiu; Tingting Wang; Jun Wang; Ming Liu; Yuxue Xu; Chao Wang; Ran Deng; Kent Williams; Zhiwei Yang; Tiebing Liang; Weidong Yong
Journal:  Biochem Biophys Res Commun       Date:  2017-02-27       Impact factor: 3.575

7.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

8.  Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis.

Authors:  S K Srivastava; A Bhardwaj; S Arora; N Tyagi; A P Singh; J E Carter; J G Scammell; Ø Fodstad; S Singh
Journal:  Br J Cancer       Date:  2015-05-05       Impact factor: 7.640

9.  Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study.

Authors:  Jian-Jun Li; Jie Luo; Jing-Ning Lu; Xiao-Na Liang; Yi-Huan Luo; Yong-Ru Liu; Jie Yang; Hua Ding; Gui-Hui Qin; Li-Hua Yang; Yi-Wu Dang; Hong Yang; Gang Chen
Journal:  Cancer Cell Int       Date:  2016-09-29       Impact factor: 5.722

10.  Ochratoxin A induces liver inflammation: involvement of intestinal microbiota.

Authors:  Wence Wang; Shuangshuang Zhai; Yaoyao Xia; Hao Wang; Dong Ruan; Ting Zhou; Yongwen Zhu; Hongfu Zhang; Minhong Zhang; Hui Ye; Wenkai Ren; Lin Yang
Journal:  Microbiome       Date:  2019-11-28       Impact factor: 14.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.